WO1999022722A2 - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents
Use of macrolides for the treatment of cancer and macular degeneration Download PDFInfo
- Publication number
- WO1999022722A2 WO1999022722A2 PCT/US1998/023043 US9823043W WO9922722A2 WO 1999022722 A2 WO1999022722 A2 WO 1999022722A2 US 9823043 W US9823043 W US 9823043W WO 9922722 A2 WO9922722 A2 WO 9922722A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- heteroaryl
- aryl
- previously defined
- alkyl
- Prior art date
Links
- 0 CC[C@@]([C@@](C)(*)[C@@]([C@@](C)C([C@](C)C[C@@](C)[C@@]([C@@](C)[C@@]([C@@]1C)O[C@@](C[C@@]2(C)O*)O[C@@](C)[C@]2O)O[C@@]([C@@]2O)O[C@](C)CC2N(C)C)=*)O)OC1=O Chemical compound CC[C@@]([C@@](C)(*)[C@@]([C@@](C)C([C@](C)C[C@@](C)[C@@]([C@@](C)[C@@]([C@@]1C)O[C@@](C[C@@]2(C)O*)O[C@@](C)[C@]2O)O[C@@]([C@@]2O)O[C@](C)CC2N(C)C)=*)O)OC1=O 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU12067/99A AU1206799A (en) | 1997-10-31 | 1998-10-30 | Use of macrolides for the treatment of cancer and macular degeneration |
IL13551898A IL135518A0 (en) | 1997-10-31 | 1998-10-30 | Use of macrolides for the treatment of cancer and macular degeneration |
BR9813318-7A BR9813318A (en) | 1997-10-31 | 1998-10-30 | Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient |
EP98955206A EP1027060A2 (en) | 1997-10-31 | 1998-10-30 | Use of macrolides for the treatment of cancer and macular degeneration |
KR1020007004625A KR20010031577A (en) | 1997-10-31 | 1998-10-30 | Use of macrolides for the treatment of cancer and macular degeneration |
PL98340604A PL340604A1 (en) | 1997-10-31 | 1998-10-30 | Application of macrolydes in treating tumours and maculopathy |
SK617-2000A SK6172000A3 (en) | 1997-10-31 | 1998-10-30 | Use of macrolides for the treatment of cancer and macular degeneration |
JP2000518656A JP2001521891A (en) | 1997-10-31 | 1998-10-30 | Use of macrolides for treating tumors and macular degeneration |
CA002307850A CA2307850A1 (en) | 1997-10-31 | 1998-10-30 | Use of macrolides for the treatment of cancer and macular degeneration |
HU0100012A HUP0100012A3 (en) | 1997-10-31 | 1998-10-30 | Use for macrolides for the treatment of cancer and macular degeneration |
NO20002189A NO20002189L (en) | 1997-10-31 | 2000-04-27 | Use of macrolides for the treatment of cancer and mucous degeneration |
BG104436A BG104436A (en) | 1997-10-31 | 2000-05-15 | The administration of macrolides for the treatment of cancer and macular degeneration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96147397A | 1997-10-31 | 1997-10-31 | |
US08/961,473 | 1997-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999022722A2 true WO1999022722A2 (en) | 1999-05-14 |
WO1999022722A3 WO1999022722A3 (en) | 1999-08-05 |
Family
ID=25504514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/023043 WO1999022722A2 (en) | 1997-10-31 | 1998-10-30 | Use of macrolides for the treatment of cancer and macular degeneration |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1027060A2 (en) |
JP (1) | JP2001521891A (en) |
KR (1) | KR20010031577A (en) |
CN (1) | CN1278178A (en) |
AR (1) | AR043071A1 (en) |
AU (1) | AU1206799A (en) |
BG (1) | BG104436A (en) |
BR (1) | BR9813318A (en) |
CA (1) | CA2307850A1 (en) |
HU (1) | HUP0100012A3 (en) |
IL (1) | IL135518A0 (en) |
NO (1) | NO20002189L (en) |
PL (1) | PL340604A1 (en) |
SK (1) | SK6172000A3 (en) |
TR (1) | TR200001147T2 (en) |
WO (1) | WO1999022722A2 (en) |
ZA (1) | ZA989885B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005030205A1 (en) * | 2003-09-19 | 2005-04-07 | Advanced Ocular Systems Limited | Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
WO2005085266A2 (en) * | 2004-02-27 | 2005-09-15 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
US7091196B2 (en) | 2002-09-26 | 2006-08-15 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7482137B2 (en) | 2000-04-13 | 2009-01-27 | Biotica Technology Limited | Hybrid glycosylated products and their production and use |
US7833966B2 (en) | 2005-07-18 | 2010-11-16 | Peyman Gholam A | Enhanced ocular neuroprotection and neurostimulation |
US7943800B2 (en) | 2003-03-28 | 2011-05-17 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs and uses thereof |
US8163726B2 (en) | 2002-09-18 | 2012-04-24 | University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
US8188141B2 (en) | 2004-09-23 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Isomigrastatin analogs in the treatment of cancer |
US8278281B2 (en) | 2005-08-24 | 2012-10-02 | Rib-X Pharmaceuticals, Inc. | Triazole compounds and methods of making and using the same |
US8470985B2 (en) | 2005-08-24 | 2013-06-25 | Rib-X Pharmaceuticals, Inc. | Triazole compounds and methods of making and using the same |
US8486960B2 (en) | 2006-03-23 | 2013-07-16 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US8658667B2 (en) | 2006-02-09 | 2014-02-25 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
US8927005B2 (en) | 2005-02-09 | 2015-01-06 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8957056B2 (en) | 2004-05-25 | 2015-02-17 | Sloan-Kettering Instiute For Cancer Research | Migrastatin analogs in the treatment of cancer |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108101948A (en) * | 2004-02-27 | 2018-06-01 | 瑞伯-X医药品有限公司 | Macrocyclic compound and its making and use method |
CN106317146B (en) * | 2015-06-18 | 2019-06-21 | 沈阳药科大学 | Bicyclic clarithomycin derivative and its as tumour cell increment inhibitor purposes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0426029A1 (en) * | 1989-10-30 | 1991-05-08 | Abbott Laboratories | Injectable formulation for lipophilic drugs |
US5498424A (en) * | 1994-11-30 | 1996-03-12 | Klein; Ira | Method of treating obesity |
-
1998
- 1998-10-29 AR ARP980105434A patent/AR043071A1/en unknown
- 1998-10-29 ZA ZA989885A patent/ZA989885B/en unknown
- 1998-10-30 EP EP98955206A patent/EP1027060A2/en not_active Withdrawn
- 1998-10-30 CN CN98810825A patent/CN1278178A/en active Pending
- 1998-10-30 PL PL98340604A patent/PL340604A1/en unknown
- 1998-10-30 BR BR9813318-7A patent/BR9813318A/en not_active Application Discontinuation
- 1998-10-30 WO PCT/US1998/023043 patent/WO1999022722A2/en not_active Application Discontinuation
- 1998-10-30 CA CA002307850A patent/CA2307850A1/en not_active Abandoned
- 1998-10-30 KR KR1020007004625A patent/KR20010031577A/en not_active Application Discontinuation
- 1998-10-30 AU AU12067/99A patent/AU1206799A/en not_active Abandoned
- 1998-10-30 SK SK617-2000A patent/SK6172000A3/en unknown
- 1998-10-30 TR TR2000/01147T patent/TR200001147T2/en unknown
- 1998-10-30 IL IL13551898A patent/IL135518A0/en unknown
- 1998-10-30 JP JP2000518656A patent/JP2001521891A/en not_active Withdrawn
- 1998-10-30 HU HU0100012A patent/HUP0100012A3/en unknown
-
2000
- 2000-04-27 NO NO20002189A patent/NO20002189L/en unknown
- 2000-05-15 BG BG104436A patent/BG104436A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0426029A1 (en) * | 1989-10-30 | 1991-05-08 | Abbott Laboratories | Injectable formulation for lipophilic drugs |
US5498424A (en) * | 1994-11-30 | 1996-03-12 | Klein; Ira | Method of treating obesity |
Non-Patent Citations (2)
Title |
---|
J. YATSUNAMI ET AL.: "Clarithromycin is a potent inhibitor of tumor-induced angiogenesis." RES. EXP. MED, vol. 197, no. 4, 1997, pages 189-197, XP002101275 * |
T. ISHII ET AL.: "TAN-1323 C and D, new concanamycin-group antibiotics: detection of the angiostatic activity with a wide range of macrolide antibiotics." J. ANTIBIOT., vol. 48, no. 1, 1995, pages 12-20, XP002101276 * |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7482137B2 (en) | 2000-04-13 | 2009-01-27 | Biotica Technology Limited | Hybrid glycosylated products and their production and use |
US8618088B2 (en) | 2002-09-18 | 2013-12-31 | University Of Pennsylvania | Methods of inhibiting choroidal neovascularization |
US8163726B2 (en) | 2002-09-18 | 2012-04-24 | University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
US7091196B2 (en) | 2002-09-26 | 2006-08-15 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
US7335753B2 (en) | 2002-09-26 | 2008-02-26 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US8202911B2 (en) | 2003-03-28 | 2012-06-19 | Cornell Research Foundation, Inc. | Migrastatin analog compositions and uses thereof |
US8835693B2 (en) | 2003-03-28 | 2014-09-16 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs and uses thereof |
US7943800B2 (en) | 2003-03-28 | 2011-05-17 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs and uses thereof |
US8324284B2 (en) | 2003-03-28 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs and uses thereof |
US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
WO2005030205A1 (en) * | 2003-09-19 | 2005-04-07 | Advanced Ocular Systems Limited | Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
WO2005085266A2 (en) * | 2004-02-27 | 2005-09-15 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
JP2007525520A (en) * | 2004-02-27 | 2007-09-06 | リブ−エックス ファーマシューティカルズ,インコーポレイテッド | Macrocyclic compounds and methods of making and using them |
US8202843B2 (en) | 2004-02-27 | 2012-06-19 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
JP2014208707A (en) * | 2004-02-27 | 2014-11-06 | メリンタ セラピューティクス,インコーポレイテッド | Macrocyclic compound and method of producing and using the same |
US8841263B2 (en) | 2004-02-27 | 2014-09-23 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
JP2018104437A (en) * | 2004-02-27 | 2018-07-05 | メリンタ・サブシディアリー・コーポレイション | Macrocyclic compounds and methods of making and using the same |
WO2005085266A3 (en) * | 2004-02-27 | 2006-01-05 | Rib X Pharmaceuticals Inc | Macrocyclic compounds and methods of making and using the same |
JP2012102147A (en) * | 2004-02-27 | 2012-05-31 | Rib-X Pharmaceuticals Inc | Macrocyclic compound and methods of making and using the same |
JP2017019786A (en) * | 2004-02-27 | 2017-01-26 | メリンタ セラピューティクス,インコーポレイテッド | Macrocyclic compounds and methods of making and using the same |
EP2716647A3 (en) * | 2004-02-27 | 2014-08-20 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
EP2716647A2 (en) * | 2004-02-27 | 2014-04-09 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
US8957056B2 (en) | 2004-05-25 | 2015-02-17 | Sloan-Kettering Instiute For Cancer Research | Migrastatin analogs in the treatment of cancer |
US8188141B2 (en) | 2004-09-23 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Isomigrastatin analogs in the treatment of cancer |
US9387165B2 (en) | 2005-02-09 | 2016-07-12 | Santen Pharmaceutical Co., Ltd. | Rapamycin formulations and methods of their use |
US9381153B2 (en) | 2005-02-09 | 2016-07-05 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8927005B2 (en) | 2005-02-09 | 2015-01-06 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US7833966B2 (en) | 2005-07-18 | 2010-11-16 | Peyman Gholam A | Enhanced ocular neuroprotection and neurostimulation |
US8202840B2 (en) | 2005-07-18 | 2012-06-19 | Minu L.L.C. | Enhanced ocular neuroprotection and neurostimulation |
US8470985B2 (en) | 2005-08-24 | 2013-06-25 | Rib-X Pharmaceuticals, Inc. | Triazole compounds and methods of making and using the same |
US9085600B2 (en) | 2005-08-24 | 2015-07-21 | Melinta Therapeutics, Inc. | Triazole compounds and methods of making and using the same |
US9006189B2 (en) | 2005-08-24 | 2015-04-14 | Melinta Therapeutics, Inc. | Triazole compounds and methods of making and using the same |
US8278281B2 (en) | 2005-08-24 | 2012-10-02 | Rib-X Pharmaceuticals, Inc. | Triazole compounds and methods of making and using the same |
US8658667B2 (en) | 2006-02-09 | 2014-02-25 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
US9452156B2 (en) | 2006-03-23 | 2016-09-27 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US8486960B2 (en) | 2006-03-23 | 2013-07-16 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
Also Published As
Publication number | Publication date |
---|---|
TR200001147T2 (en) | 2000-08-21 |
KR20010031577A (en) | 2001-04-16 |
CA2307850A1 (en) | 1999-05-14 |
ZA989885B (en) | 1999-05-05 |
NO20002189L (en) | 2000-06-28 |
EP1027060A2 (en) | 2000-08-16 |
NO20002189D0 (en) | 2000-04-27 |
CN1278178A (en) | 2000-12-27 |
PL340604A1 (en) | 2001-02-12 |
BR9813318A (en) | 2000-08-22 |
IL135518A0 (en) | 2001-05-20 |
AU1206799A (en) | 1999-05-24 |
JP2001521891A (en) | 2001-11-13 |
HUP0100012A2 (en) | 2001-05-28 |
BG104436A (en) | 2000-12-29 |
HUP0100012A3 (en) | 2003-07-28 |
AR043071A1 (en) | 2005-07-20 |
WO1999022722A3 (en) | 1999-08-05 |
SK6172000A3 (en) | 2001-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999022722A2 (en) | Use of macrolides for the treatment of cancer and macular degeneration | |
US5827895A (en) | Hexahydrolupulones useful as anticancer agents | |
JPH0349893B2 (en) | ||
US6287602B1 (en) | Treatment of oncologic tumors with an injectable formulation of a Golgi apparatus disturbing agent | |
JP2662094B2 (en) | 4 "-deoxyerythromycin derivative | |
JPH06263635A (en) | Contraceptive and menstrual cycle regulatory medicine having antineoplastic properties, its use, and its preparation | |
EP1025114B1 (en) | 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity | |
KR20010030649A (en) | CELLULAR IMMUNOGENICITY POTENTIATING COMPOSITION CONTAINING α-GLYCOSYLCERAMIDE | |
WO2005007143A2 (en) | Use of makrolides and ketolides for the treatment of tuberculosis | |
CN101855219A (en) | 6, 11-bridged biaryl macrolides | |
JPH07110874B2 (en) | Erythromycin A derivative | |
CN108883123B (en) | Glycoalkaloid combinations and various uses thereof | |
US6436906B1 (en) | 9-amino-14-membered macrolides derived from leucomycins | |
US20020019355A1 (en) | Anti-infective agents useful against multidrug-resistant strains of bacteria | |
RU2454230C2 (en) | Treatment and prevention of diseases and infections in pigs and poultry | |
HU211739A9 (en) | Antineoplastic effect potentiator and antineoplastic agent | |
CN111032035A (en) | Dosing regimen for tesetaxel and capecitabine | |
EP2852601A1 (en) | Semisynthetic derivatives of nystatin a1 | |
CZ20001524A3 (en) | Pharmaceutical preparation for treating tumors and macular degeneration | |
EP1259923B1 (en) | Anti-infective agents useful against mulitidrug-resistant strains of bacteria | |
WO2006105725A1 (en) | A combination of luteolin and one of pt chemotherapeutics | |
US6716820B1 (en) | 6-O-substituted bicyclic macrolides | |
WO2006124720A1 (en) | Multidrug resistant anticancer anthracyclines | |
WO2023134707A1 (en) | Methods for treating aml-mrc and mds | |
WO2003039537A1 (en) | Chemoprotectant compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 135518 Country of ref document: IL Ref document number: 98810825.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 503824 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12067/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-1524 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2307850 Country of ref document: CA Ref document number: 2307850 Country of ref document: CA Kind code of ref document: A Ref document number: 2000 518656 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6172000 Country of ref document: SK Ref document number: 2000/01147 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007004625 Country of ref document: KR Ref document number: 1998955206 Country of ref document: EP Ref document number: PA/A/2000/004225 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1998955206 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-1524 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007004625 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998955206 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007004625 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-1524 Country of ref document: CZ |